--- title: "Weekly Recap | Beigene -1.01%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/301470008.md" description: "Beigene fell 1.01% this week to close at $354.47, while the S&P 500 rose 1.15%, leaving the stock about 2.16 percentage points behind the benchmark. The session pattern was front-loaded then pulled back: from Monday to Wednesday the stock mostly traded between $359 and $368, before Thursday opened lower and dipped to $340.445, recovering above $350 by the close. Friday edged up to $354.47. Weekly amplitude reached 7.71%, with intraday swings widening on Thursday and Friday." datetime: "2026-10-10T07:17:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/301470008.md) - [en](https://longbridge.com/en/news/301470008.md) - [zh-HK](https://longbridge.com/zh-HK/news/301470008.md) generator: "portal-rs" --- # Weekly Recap | Beigene -1.01%, most brokers rate it buy ## The Week Beigene fell 1.01% this week to close at $354.47, while the S&P 500 rose 1.15%, leaving the stock about 2.16 percentage points behind the benchmark. The session pattern was front-loaded then pulled back: from Monday to Wednesday the stock mostly traded between $359 and $368, before Thursday opened lower and dipped to $340.445, recovering above $350 by the close. Friday edged up to $354.47. Weekly amplitude reached 7.71%, with intraday swings widening on Thursday and Friday. ## Key Events The week’s news flow centred on TEVIMBRA’s reimbursement progress and stock-specific volatility. On Tuesday, plague rumours lifted biotech names broadly; by Wednesday, a price target increase to $420.00 appeared in reports. Thursday and Friday coverage focused on whether Beigene is attractively priced after the TEVIMBRA reimbursement milestone, alongside a recap of a 5.8% single-day drop. Hong Kong-listed pharma names were mixed during the same window, with Wuxi Bio down more than 3% and Genscript Bio down 10%, pointing to uneven sentiment across the sector. Overall, company-specific catalysts this week were the reimbursement headline and external target updates, with the stock recovering part of its losses by Friday. ## Analyst Ratings Coverage of Beigene stands at 27 firms: 19 rate it buy, 7 rate it overweight, and 1 rates it hold, with no underweight or sell ratings. The consensus rating is strong buy, and the consensus target price is $435.53, about 22.87% above the latest price. Targets range from $370 to $528, showing a wide spread. Within the biotechnology industry, Beigene ranks 11th out of 508 names, placing it near the top of the group. ## The Week Ahead Next week’s macro calendar is concentrated on Tuesday and Wednesday. Tuesday brings the NFIB small business optimism index and existing home sales; Wednesday features CPI and core CPI, with core CPI seen at 2.5 versus 2.4 prior and headline CPI at 3.7 versus 3.4 prior. These inflation prints will shape rate expectations. On the company side, Beigene’s fiscal Q3 2026 results are scheduled for 10 November before market open, with consensus estimates at EPS of $1.8912 and revenue of $1.756 billion. ## In Short Beigene’s week presents a tension: the consensus target sits more than 22% above spot, and 26 of 27 covering firms rate it buy or overweight, a broadly supportive rating backdrop. Yet the latest session’s money flow is mixed, with small and medium orders recording net selling while large orders show some net buying. Against the S&P 500, the stock underperformed this week. What matters next is how biotech risk appetite responds to the CPI data, and whether the Q3 report on 10 November supports current valuations. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) ## Related News & Research - [BeOne stock breaks out with visions of 177% earnings growth. This telltale clue bodes well.](https://longbridge.com/en/news/302773305.md) - [BeOne Reports 36% Response Rate for BGB-B2033 in Phase 1 Liver Cancer Trial](https://longbridge.com/en/news/302957977.md) - [BeOne Medicines Ltd. Unveils ESMO Data, Targets HCC Registration in 2026](https://longbridge.com/en/news/302958159.md) - [BeOne Medicines’ Tevimbra Combination Extends Median Survival to 27 Months in Gastroesophageal Cancer Trial](https://longbridge.com/en/news/302895730.md) - [BeOne Medicines Ltd. Posts Sustained OS Benefit in Phase 3 HER2+ GEA Trial](https://longbridge.com/en/news/302896408.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**